Evaluation of Dose Response Relationship, Safety and Efficacy of GSK1278863 in Hemodialysis-dependent Subjects With Chronic Kidney Disease Associated Anemia
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 216 participants.
Also called NCT01977482
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 216 participants
- Sponsor
- Registry
-
NCT01977482
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Australia, Canada, Czechia, Denmark, France, Germany, Hungary, Japan, Norway, Poland, Russia, South Korea, Spain, Sweden, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT01977482. Randomized; triple masking; primary purpose treatment. Start 2013-11-01 (registry gives no type); primary completion 2015-02-01 (actual). Results posted on 2017-02-14.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Evaluation of Dose Response Relationship, Safety and Efficacy of GSK1278863 in Hemodialysis-dependent Subjects With Chronic Kidney Disease Associated Anemia
- Condition
- Anaemia
- Intervention (Drug)
- GSK1278863
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- rhEPO
- Lead sponsor
- GlaxoSmithKline
Record details
- Record id
cardio:ct-nct01977482- Content hash
5337a0f4c23700bdde82139adccc06162acfb9921037f710a47ef45dccd1886f